Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. [electronic resource]
Producer: 20110823Description: S63-71 p. digitalISSN:- 0392-856X
- Adult
- Aged
- Antibodies, Monoclonal -- adverse effects
- Antibodies, Monoclonal, Murine-Derived -- adverse effects
- Chi-Square Distribution
- Drug Resistance
- Drug Substitution
- Female
- France
- Granulomatosis with Polyangiitis -- diagnosis
- Humans
- Immunosuppressive Agents -- adverse effects
- Infliximab
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Patient Selection
- Prospective Studies
- Recurrence
- Remission Induction
- Risk Assessment
- Risk Factors
- Rituximab
- Severity of Illness Index
- Time Factors
- Treatment Outcome
- Young Adult
No physical items for this record
Publication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.